Skip to content

Study · Systematic review · 2023

2 results

Effects of intranasal oxytocin on pain perception among human subjects: A systematic literature review and meta-analysis.

Lopes S, Osório FL

Hormones and behavior1 Dec 2022Cited by 9 (Europe PMC)

PMID36463692 (opens in a new tab)DOI10.1016/j.yhbeh.2022.105282 (opens in a new tab)PepBankPUB-36463692
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of human studies, intranasal oxytocin had no statistically significant effect on pain intensity.

    In plain wordsIn a pooled analysis of human studies, oxytocin nasal spray did not change how intense pain felt.

    Peptide
    Oxytocin
    Outcome
    No significant changePain intensity (self-perception)
    Study

    n: not reported in source

    Comparator
    Placebo or control
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    SMD
    −0.02 SMD
    pain intensity

    Source sentences

    Summary
    pain intensity (SMD = -0.02 (CI 95 %: -0.14 to 0.10; p = 0.76))
    1 context sentence
    Summary · context
    Fifteen papers were included in the meta-analysis.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of human studies, intranasal oxytocin had no statistically significant effect on pain unpleasantness.

    In plain wordsIn a pooled analysis of human studies, oxytocin nasal spray did not change how unpleasant pain felt.

    Peptide
    Oxytocin
    Outcome
    No significant changePain unpleasantness (self-perception)
    Study

    n: not reported in source

    Comparator
    Placebo or control
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    SMD
    −0.15 SMD
    pain unpleasantness

    Source sentences

    Summary
    pain unpleasantness (SMD = -0.15 (CI 95 %: -0.34 to 0.04; p = 0.12)).
    1 context sentence
    Summary · context
    Fifteen papers were included in the meta-analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.